Historically, the survival of children and adolescents with Burkitt's and Burkitt-like lymphoma had been poor. Recently, short and intensive chemotherapy appears to have improved disease outcome. We therefore reviewed the results of four successive Children's Cancer Group trials conducted on 470 children with disseminated Burkitt's and Burkitt-like lymphoma. Of the patients studied, the median age was 8 years (0-21 years), the male:female ratio was 4:1, 58% had lactate dehydrogenase (LDH) > or = 500 IU/l, 23% had M2 or M3 bone marrow (BM), and 12% demonstrated central nervous system involvement. In a multivariate analysis, the 4-year event-free survival (EFS) in patients > or = 15-years-old compared with < 15-year-old was 34 +/- 7 versus 59 +/- 2% (P < 0.05), the 4-year EFS of M2/M3 compared with M1 BM was 38 +/- 5 versus 63 +/- 3% (P < 0.001), and the 4-year EFS with LDH > or = 500 IU/l compared with LDH < 500 IU/l was 49 +/- 3 versus 71 +/- 4% (P < 0.001). Furthermore, patients treated on the most recent protocol, which was short and more intensive, had a significantly improved survival compared with those on previous trials (4-year EFS 80 +/- 6 versus 54 +/- 2%, P < 0.001). In summary, the outcome for childhood Burkitt's and Burkitt-like lymphoma has recently improved with the use of short and intensive B-cell non-Hodgkin's lymphoma-directed therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.2003.04134.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunodeficiency-related high-grade B-cell lymphoma with 11q aberration: Further evidence for a lymphoma entity from a patient with simultaneous papillary renal cell carcinoma following pediatric kidney transplant.
Pathol Res Pract
December 2024
Section of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy. Electronic address:
Various aggressive lymphomas entities have been associated with immunodeficiency. To provide further evidence that also MYC-negative high-grade B-cell (formerly Burkitt-like) lymphoma with 11q aberrations comprises an immunodeficiency-related subtype, we here conducted a comprehensive pathological and genetic workup of a 25-year-old patient with this type of lymphoma and simultaneous papillary renal cell carcinoma. The patient developed both malignancies following extensive childhood immunosuppression and a kidney transplant.
View Article and Find Full Text PDFNon-Hodgkin's primary lymphoma involving the genitourinary tract: histopathological experience from two tertiary hospitals, Western region, Saudi Arabia.
Am J Clin Exp Urol
October 2024
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center Jeddah, Saudi Arabia.
Article Synopsis
- The study focuses on primary lymphoid neoplasms in the urinary tract and male genital organs, which are rare and make up less than 5% of extranodal lymphomas.
- Researchers analyzed cases diagnosed from 2005 to 2020, examining pathology slides from 11 patients, predominantly middle-aged, finding a female predominance in urinary bladder and ureter lymphomas.
- The findings confirm that diffuse large B-cell lymphoma (DLBCL) is the most common subtype, but emphasize the importance of thorough classification and diagnosis using techniques like immunohistochemistry to accurately identify various lymphoma types.
[Clinicopathological characteristics of angioimmunoblastic T-cell lymphoma with B-cell proliferation or neoplasms].
Zhonghua Bing Li Xue Za Zhi
July 2024
Department of Pathology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Article Synopsis
- - The study examines angioimmunoblastic T-cell lymphoma (AITL) cases with a focus on their clinical, pathological, and immunophenotypic characteristics, as well as the differential diagnosis involving B-cell proliferation or neoplasms.
- - Eight cases from a hospital in China were analyzed, revealing one case of AITL with diffuse large B-cell lymphoma (DLBCL) and seven cases of AITL with B-cell proliferation, with an average patient age of 58 years.
- - The findings highlight distinct histological features and tumor behavior in AITL with B-cell involvement, suggesting that a combination of clinical, morphological, and molecular analyses is essential for accurate diagnosis.
Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience.
Pediatr Blood Cancer
August 2024
The Royal Marsden Hospital, Sutton, London, UK.
Article Synopsis
- Monomorphic post-transplant lymphoproliferative disorder (mPTLD) is a significant health risk after solid organ transplants, with challenges in balancing treatment intensity and risks like infection and organ rejection.* -
- A study analyzed 56 children with mPTLD treated with low-intensity therapies in the UK and Spain, finding that 92.8% survived for one year, despite 78.6% presenting with advanced disease.* -
- The results indicate that R-COP, a low-dose chemotherapy, is an effective initial treatment, with escalation to more aggressive approaches beneficial for those who do not adequately respond.*
Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
PLoS Pathog
April 2024
Department of Oncology, McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin Madison, Madison, Wisconsin, United States of America.
Epstein-Barr virus (EBV) is an important cause of human lymphomas, including Burkitt lymphoma (BL). EBV+ BLs are driven by Myc translocation and have stringent forms of viral latency that do not express either of the two major EBV oncoproteins, EBNA2 (which mimics Notch signaling) and LMP1 (which activates NF-κB signaling). Suppression of Myc-induced apoptosis, often through mutation of the TP53 (p53) gene or inhibition of pro-apoptotic BCL2L11 (BIM) gene expression, is required for development of Myc-driven BLs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!